Effects of NSK-SD (Nattokinase) on Blood Pressure

Last updated: August 31, 2016
Sponsor: Natural Immune Systems Inc
Overall Status: Completed

Phase

4

Condition

Circulation Disorders

Stress

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT02886507
NIS 087-001
  • Ages 18-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a randomized double-blinded placebo-controlled study to evaluate the effects of NSK-SD consumption in subjects with Stage I hypertension.

The study population will be randomized into two groups, where both groups will receive dietary and lifestyle recommendations to help reduce hypertension. One group will receive placebo and the other group NSK-SD for 8 weeks.

The endpoint will be the change in systolic and diastolic blood pressure after 8 weeks of treatment in the two subject groups.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy adults of both genders;

  • Age 18-85 years;

  • Elevated blood pressure as identified by:

  • Systolic blood pressure 130mmHg or higher, or diastolic blood pressure 90mmHg orhigher;

  • Confirmed on three separate occasions.

Exclusion

Exclusion Criteria:

  • Use of Nattokinase-containing supplements within 60 days prior to enrollment;

  • Currently on blood pressure medication;

  • History of cancer chemotherapy within the last 12 months;

  • Significant active uncontrolled disease (such as lymphoma, cirrhosis, nephritis,uncompensated heart failure);

  • Consumption of more than an average of 2 standard alcoholic drinks/day (14 drinks perweek)

  • Currently experiencing intense stressful events/ life changes that would negativelyaffect compliance;

  • Pregnant, nursing, or trying to become pregnant;

  • Women not using effective contraception;

  • Food allergies related to ingredients in test product.

Study Design

Total Participants: 79
Study Start date:
March 01, 2012
Estimated Completion Date:
June 30, 2014

Study Description

Previous randomized double blinded placebo-controlled studies on the consumption of the fibrinolytic enzyme Nattokinase and NSK-SD is transported across the gut, and has shown multiple effects on vascular health, including fibrinolytic effects and regulation of blood pressure.

A previous study on effects on blood pressure was conducted in an Asian population involving 86 people, where 73 people completed the study requirements (39 in the NSK-SD group, 34 in the placebo group). The data showed statistically significant reduction in both systolic and diastolic blood pressure after consumption of Nattokinase, whereas the changes after consuming placebo were not significantly different from baseline.

The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North American hypertensive population with associated genetic, dietary, and lifestyle factors. This is in extension of, and contrast to, previous studies in Asian populations.